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Dr A. Peter Kappetein (Rotterdam, The Netherlands). The
conflict of interest that I have to report is that I am a member of
the steering committee of the RE-ALIGN (The Randomized,
Phase II Study to Evaluate the Safety and Pharmacokinetics
of Oral Dabigatran Etexilate in Patients After Heart Valve
Replacement) trial, which tested dabigatran in patients with
mechanical heart valves.
Dear Dr Puskas, thank you very much for your excellent
presentation and thank you for sending the report in advance of
this meeting. Treatment with oral anticoagulant drugs is effective
in the prevention of TE but inevitably increases the risk of bleeding
events. Although low-dose anticoagulation leads to more
thromboembolic events, a dosage that is too high can lead to
hemorrhage. Anticoagulation monitoring and adjustment of the
dosage is therefore steering safely between Scylla and Charybdis.
The trial that you just presented is a noninferiority trial.
The difficulty with this type of study design is choosing the
right noninferiority margin, the so-called delta. Because no
meaningful data are available comparing warfarin to placebo
with prosthetic heart valves, there is no ability to construct
additional noninferiority boundaries.
Your sample size estimation was based on a 1-sided proportion
test with type 1 error of 0.05 and a power of 80% to test this
noninferiority hypothesis with an absolute noninferiority margin
of 1.5%. The event rates on which you based your sample size
calculation were not mentioned in the report; however, usually
the TE rates will be as high as 3% to 4% annually among
mechanical valve patients, and valve thrombosis can occur in
0.5% of mechanical valve patients annually. In contemporary
practice, the risk of significant hemorrhage has been reported at
2% to 3%. The number of patients in your trial was extremely1210 The Journal of Thoracic and Cardiovascular Surlow, only 375 divided into 2 arms. The comment and question
that I have are the following.
When you lower the anticoagulation treatment, you will always
lower the bleeding events, no doubt about this, although the valve
thrombosis and thromboembolic events could increase. However,
you cannot put 2 events in a composite endpoint of a noninferiority
trial if they do not point in the same direction. It might well be that
bleeding events will decrease more than thromboembolic events
will increase. In this study, you mixed the efficacy endpoints
with the safety endpoints.
During the past couple of years, new anticoagulant drugs have
been tested against warfarin in patients with atrial fibrillation.
The thromboembolic events were even greater than those in the
patients with mechanical heart valves, and these studies more or
less used the same noninferiority margin that you used in your
study. However, these studies included many more patients:
ARISTOTLE (Apixaban vs Warfarin in patients with Atrial
Fibrillation), 18,000 patients; ROCKET (Rivaroxaban Once Daily
Oral Direct Factor Xa Inhibition Compared With Vitamin K
Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation), 14,000 patients; and RELY (Randomized Evaluation
of Long-Term Anticoagulation Therapy), 15,000 patients. You
could have saved those companies a lot of money with your study
design.
My question is, should we regard this trial as a pilot study and
should we not base the sample size only on the efficacy endpoint,
being thromboembolic events, and in that case, should we design a
new trial and increase the sample size to around 8000 patients and
try to find the money for the trial somewhere? Is it not potentially
dangerous if we do not know what the increase is of valve
thrombosis and follow your conclusions?
Then another question. Should a third arm of the new trial include
one of the new anticoagulant drugs?What do you think is the reason
that dabigatran worked in the patients with atrial fibrillation but did
not work in the patients with mechanical heart valves?
Thank you very much.
Dr Puskas. Thank you, Pieter. I share your concern about a
noninferiority design for our trial. It was certainly a topic of
much discussion with the FDA 8 years ago when this trial
was designed and approved by the FDA. As you commented,
thrombotic events and hemorrhagic events were not moving in
the same direction, and this is just as we would expect. I showed
a slide that recapitulates old studies that showed that thrombotic
events move in one direction and bleeding events in the other.
What we are really looking for is to determine a ‘‘sweet spot’’
where those 2 curves intersect. Although it is theoretically or
intellectually correct to say that thrombosis is the efficacy issue
and hemorrhage the safety issue, we were obliged to combine
those, for 2 reasons. First, the practical reason, no company will
sponsor an 8000-patient, randomized trial; and second, the clinical
reason, this was in fact a tradeoff in the minds of the patients
and clinicians. So, it is a relevant clinical endpoint, this unholy
composite, if you will, of thrombosis and hemorrhage.
The factors that affect bleeding are probably valve independent
for the most part. They relate to the patient and the anticoagulant
administered. The factors that affect thromboembolism or throm-
bosis include the above and patient factors and factors related to
the therapy administered; however, they also involve, importantly,gery c April 2014
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investigational device exemption is trying to study the valve and
whether this particular valve has a different ‘‘sweet spot’’ in terms
of the risk of bleeding and thrombosis relative to other valves.
Now, I do not work for the company; I have no financial
relationship with the company. I am impressed by the design of
the valve from an engineering point of view and from a materials
point of view. The present study really was to determine whether
that difference in design will move the TE curve along the bleeding
curve such that the ‘‘sweet spot’’ would be lower and more
attractive to patients and clinicians. I think that is an appropriate
answer to your first question.
In terms of your second question, why did dabigatran not work; I
am amazed it did not work. One of the elements of that trial was that
double valves were allowed. It was sort of an ‘‘all-comers’’ type of
trial. I wonder if that had been held strictly to isolated AVR or
isolated mitral valve replacement, whether you might have had a
different result. However, direct thrombin inhibitors are relatively
new, and we do not understand them as well as we understand
warfarin, which has been around for 40 years. Another possible
explanationmight relate to the relatively short half-life of dabigatran
and that the dabigatran trial did not include aspirin administration. A
patient in the dabigatran trial who skipped 1 or 2 doses of dabigatran
with, for example, a double mechanical valve replacement, is
immediately at high risk of a thrombotic event. In contrast, a patient
who skips 1 dose ofwarfarinwhile also taking aspirin is probably at a
lesser immediate risk of thromboembolic events. The increased
hemorrhagic complications seen in the dabigatran trial might have
been related to the rather high dose of the drug given in that trial.
However, these explanations are speculative.
Dr Hartzell V. Schaff (Rochester, Minn). In one of the slides I
think I saw that you had 6 reoperations in 1 group.What were those
for?
Dr Puskas. Early reoperation for bleeding was the most
common perioperative event, and those were typically before
randomization.
Dr Michael A. Acker (Philadelphia, Pa). One of the key
elements to your design was point of care testing at home for
both groups. That is not universally done; in fact, I would say
across the United States, that is unusual. Do you think these results
would hold up, given a standard practice of managing it, because
that type of tight control is probably not the real world.
Dr Puskas. It (point-of-care home INR testing) is not the real
world in America now. It is the real world in Scandinavia andThe Journal of Thoracic and Carsome other regions. So, I think your comment is absolutely well
taken, Mike.
We found in careful analysis of the 53,000 INR endpoints that
we have and correlating those with adverse events that the
variability in INR is very important in affecting adverse events,
both bleeding and clotting, and it seems to be more impactful
than the actual mean INR. Whether you are in the test group,
with an INR of 1.5 to 2, or in the control group, INR 2 to 3, it would
seem to matter more whether you are good about doing your
testing and controlling your INR in your range than which range
you are in. Bleeding events can occur after a relatively brief period
high outside the range; hemorrhagic events are particularly
sensitive to (poor) INR control.
I think that we in America need to catch up with what should be
considered the standard of care in other parts of the world. Home
INR monitoring is available, it is not high tech, and it is much
easier for patients. To be perfectly blunt, there is really no excuse
for us not using it uniformly in America.
Dr Acker. There is a reimbursement issue, as you know.
Dr Puskas. It, quite frankly, is a conflict of interest for local
care providers and their patients’ well-being. A small revenue
stream occurs to cardiology offices and primary care doctors
running warfarin clinics, and that is keeping us in the system
that we have now rather than home INRmonitoring through larger,
centralized warfarin clinics. The coordination of home INR
monitoring and clinical care in the present trial is far better than
what I have provided to my own patients in the past. However,
with the knowledge we have gained from the PROACT trial, we
are strongly encouraging home INR monitoring for all patients
who are treated with warfarin.
DrMohamed Emara (Cairo, Egypt).Did you face the problem
that you cannot reach even this target of low INR with a large dose
of warfarin, and what type of warfarin do you use, hydrophobic or
hydrophilic?We have this problem in Egypt. Sometimes, we reach
to 11 mg and we do not reach>1.2. What is your comment about
that?
Dr Puskas. There are a small number of patients who are
relatively warfarin resistant and require large doses, but we
have not had to exclude anybody from the trial because of
an inability to anticoagulate them. The patients were encouraged
to use brand name warfarin, but not all did, and generic
warfarin was used by some patients. Thus, I cannot tell you that
everybody received exactly the same kind of warfarin. That was
not feasible.diovascular Surgery c Volume 147, Number 4 1211
